This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Early-onset cerebellar ataxia (other types)Early-onset Cerebellar Ataxia (Other Types)

Contents and key points
ItemDetails
A. Classification codesICD-10: G11.1 | Special Copayment Reduction: V123
B. SynonymsEarly-onset cerebellar ataxia (onset usually before age 20), X-linked recessive spinocerebellar ataxia, early-onset cerebellar ataxia with retained tendon reflexes, early-onset cerebellar ataxia with myoclonus [Hunt ataxia], early-onset cerebellar ataxia with essential tremor
C. Adult onsetFirst onset in adulthood unlikely — onset usually before age 20; some types may begin up to the 20s
1. HistoryDevelopment of the classification of early-onset ataxias other than Friedreich; history of the individual descriptions of ARSACS, DRPLA, Roussy-Levy and others
2. CausesVarious gene mutations (SACS, ATN1, PMP22, etc.), genetic heterogeneity, differing etiology for each subtype
3. GeneticsAutosomal recessive (ARSACS, recessive form of DRPLA), autosomal dominant (some Roussy-Levy), X-linked recessive, etc.
4. General epidemiologyLow prevalence for each subtype; regional founder effects (ARSACS—Charlevoix, Canada); DRPLA relatively frequent in East Asia
5. PathophysiologyDiffers by subtype: loss of protein function (ARSACS), polyQ toxicity (DRPLA), myelin abnormality (Roussy-Levy), etc.
6. SymptomsCerebellar ataxia + subtype-specific symptoms: spasticity (ARSACS), myoclonus (Hunt), tremor (Roussy-Levy), etc.
7. SignsSigns of cerebellar ataxia + additional neurologic signs by subtype; tendon reflexes preserved or brisk (ARSACS)
8. ScreeningGene panel testing, imaging and electrophysiologic studies in patients with early-onset ataxia
9. DiagnosisSubtype-specific molecular genetic testing, brain MRI, nerve conduction studies, clinical exome sequencing
10. TreatmentMostly symptomatic treatment (rehabilitation, seizure control, treatment of spasticity); specific treatments tried in some subtypes
11. PrognosisVaries by subtype; mostly progressive; very poor prognosis in early-onset DRPLA
12. PreventionGenetic counseling; family testing and prenatal diagnosis according to the inheritance pattern of each subtype
13. ReferencesBeaudin M et al. Lancet Neurol 2022 and 9 other papers

1. History

The other types of early-onset cerebellar ataxia began to be described individually after Friedreich ataxia was elucidated molecularly, when it was recognized that separate genetic diseases exist in patient groups that do not meet the Friedreich criteria. In the early 20th century, Roussy-Levy syndrome was described as a familial disease presenting with ataxia, tremor and areflexia, and its association with Charcot-Marie-Tooth disease was later revealed.

Myoclonic ataxia described by Hunt in 1978 (dyssynergia cerebellaris myoclonica, Hunt ataxia) is a syndrome combining seizures, myoclonus and cerebellar ataxia, and it was later shown that various causative diseases fall under this syndrome. ARSACS (autosomal recessive spastic ataxia of Charlevoix-Saguenay), common in the Charlevoix-Saguenay region of Quebec, Canada, was known as a region-specific genetic disease even before the SACS gene was identified in 2000.

Dentatorubral-pallidoluysian atrophy (DRPLA), relatively common in Japan and East Asia, was identified in 1994 as a CAG repeat expansion in the ATN1 gene. In addition, as numerous genotypes such as X-linked recessive spinocerebellar ataxia (SCAX) have been discovered one after another, the group of other early-onset ataxias in the G11.1 category is being subdivided clinically and genetically.

2. Causes

The causes of other types of early-onset cerebellar ataxia differ by subtype. The most important subtypes, classified by etiology, are as follows.

ARSACS (autosomal recessive spastic ataxia of Charlevoix-Saguenay) is caused by loss of function of the sacsin protein due to mutations in the SACS gene on chromosome 13 (13q11). Sacsin has chaperone function and is essential for the development of cerebellar Purkinje cells. DRPLA (dentatorubral-pallidoluysian atrophy) is caused by polyglutamine toxicity of the atrophin-1 protein due to CAG repeat expansion in the ATN1 gene (12p13.31). The childhood-onset form has a large CAG repeat number (>65) and is characterized by progressive myoclonic seizures, ataxia, seizures and dementia.

Roussy-Levy syndrome mostly falls within the CMT disease spectrum caused by mutations in the PMP22 or MFN2 gene and is a phenotype combining ataxia and tremor. Myoclonic ataxia (Hunt ataxia) can have various causes, such as mitochondrial disease, MERRF syndrome, neuronal ceroid lipofuscinosis and Unverricht-Lundborg disease. X-linked recessive spinocerebellar ataxia (SCAX) is caused by mutations in X-chromosome genes such as ABCB7 and ATP2B3.

3. Genetics

The other types of early-onset cerebellar ataxia include various inheritance patterns. ARSACS is autosomal recessive and develops only when both SACS alleles carry mutations. Its prevalence is high in the Charlevoix-Saguenay region of Canada because of a founder effect. DRPLA is a CAG repeat expansion in the ATN1 gene, showing autosomal dominant inheritance and strong anticipation. The childhood-onset form usually results from paternal transmission with a large increase in the CAG repeat number.

In Roussy-Levy syndrome, PMP22 duplication is the most common cause, with autosomal dominant inheritance. X-linked recessive spinocerebellar ataxia is inherited in an X-linked manner, affecting mainly males, while female carriers are mildly affected or asymptomatic. For early-onset ataxia with essential tremor, GAA repeat expansion in the FGF14 gene (SCA27B) was recently discovered and may be included in this category in some cases.

The genetic causes of early-onset ataxia overall (excluding Friedreich) are increasingly being identified through clinical exome and genome sequencing, but a considerable number of cases still have no known gene. Associated neurologic signs (spasticity, myoclonus, peripheral nerve abnormalities, etc.), age of onset, rate of progression and family history are important for prioritizing genetic testing.

4. General epidemiology

The prevalence of each of the other types of early-onset cerebellar ataxia is very low. ARSACS has a high prevalence of about 1/1,700 in the Charlevoix-Saguenay region of Quebec, Canada, because of a founder effect, and is rare elsewhere. Several hundred patients have been reported worldwide, a number that is increasing with the spread of genetic testing. DRPLA occurs more frequently in Japan and East Asia than in Western countries, with a prevalence in Japan of about 0.2/100,000–0.5/100,000. Childhood-onset DRPLA accounts for part of all DRPLA.

Because Roussy-Levy syndrome falls within the CMT spectrum, there are no separate independent prevalence statistics. The overall prevalence of CMT is about 1/2,500, and the proportion with the Roussy-Levy phenotype is small. X-linked spinocerebellar ataxia and other rare subtypes have each been reported in only tens to hundreds of patients worldwide. In Korea, official prevalence data for each of these diseases are lacking, and estimation through Special Copayment Reduction V123 registration is needed.

5. Pathophysiology

The pathophysiology of the other types of early-onset cerebellar ataxia differs by subtype. In ARSACS, loss of sacsin protein function impairs axonal myelination and neuronal survival of cerebellar Purkinje cells. Sacsin is involved in protein folding and regulation of mitochondrial morphology through its heat shock protein (Hsp90) homology domains. In sacsin deficiency, excessive mitochondrial clustering in Purkinje cell axons and neuronal death occur.

In DRPLA, polyglutamine (polyQ)-expanded atrophin-1 resulting from CAG repeat expansion in the ATN1 gene forms intranuclear inclusions and interferes with the function of transcriptional regulators. This causes selective degeneration of neurons in the dentate nucleus, red nucleus, globus pallidus and subthalamic nucleus. In childhood-onset DRPLA, seizures, cognitive decline and myoclonic ataxia are the main features, with involvement of both the cerebellar cortex and the basal ganglia.

In Roussy-Levy syndrome (PMP22 abnormality), abnormal myelin formation in peripheral nerves causes sensorimotor neuropathy, which combines with cerebellar dysfunction to produce ataxia and tremor. In myoclonic ataxia, various mechanisms are involved depending on the underlying disease, such as mitochondrial dysfunction (MERRF), lysosomal storage disorders and increased neuronal excitability (UCB1/CSTB mutations).

6. Symptoms

The other types of early-onset cerebellar ataxia all share progressive cerebellar ataxia as a common symptom, but each subtype has its own specific accompanying symptoms.

ARSACS is characterized by lower-limb spasticity accompanying gait ataxia from an early stage, and unlike typical Friedreich ataxia, tendon reflexes are brisk or preserved. Peripheral neuropathy is also common, and a finding of retinal hypermyelination of optic disc fibers is characteristic.

Childhood-onset DRPLA presents with a combination of seizures, myoclonus, progressive cognitive decline, chorea and ataxia. Unlike adult DRPLA, cognitive decline and seizures are prominent from the early stage. Roussy-Levy syndrome is characterized by tremor, gait ataxia, areflexia (loss of tendon reflexes) and sensory abnormalities. Myoclonic ataxia (Hunt ataxia) is characterized by the triad of seizures, myoclonus (generalized or focal) and cerebellar ataxia. In the form with essential tremor, postural and action tremor is prominent along with ataxia.

7. Signs

On neurologic examination, subtype-specific findings are important. In ARSACS, in addition to signs of cerebellar ataxia (gait instability, limb incoordination, dysarthria), lower-limb spasticity, brisk deep tendon reflexes and a positive Babinski sign are observed. On funduscopic examination, hypermyelination of the retinal nerve fibers around the optic disc is highly specific for ARSACS.

In the childhood-onset form of DRPLA, severe myoclonic seizures are observed in addition to cerebellar findings, and electroencephalography shows generalized spike-and-wave discharges and photosensitivity abnormalities. Cognitive function testing confirms progressive decline. In Roussy-Levy syndrome, areflexia, distal sensory loss due to peripheral neuropathy and tremor of the hands and legs (intention tremor and postural tremor) are observed. In myoclonic ataxia, spontaneous and stimulus-sensitive myoclonus appears characteristically.

In X-linked forms, pedigree analysis of male patients confirms a pattern of maternal transmission, and female carriers have mild or no symptoms. Preserved or brisk tendon reflexes are an important point of differentiation from Friedreich ataxia; conversely, when tendon reflexes are lost and there are sensory nerve abnormalities, ARSACS or the Roussy-Levy group is suspected.

8. Screening

Screening for other types of early-onset cerebellar ataxia is often done in patients with progressive cerebellar ataxia beginning before age 20 after Friedreich ataxia (FXN GAA expansion) has been ruled out. Tests suited to the suspected subtype based on clinical features are performed first.

If cerebellar ataxia + spasticity + retinal abnormality are present, SACS gene mutation testing is performed first. With the combination of childhood-onset seizures + myoclonus + ataxia, testing for DRPLA (ATN1 CAG repeat) and other causes of progressive myoclonic epilepsy (MERRF, neuronal ceroid lipofuscinosis, etc.) is performed. If the family history shows a maternal transmission pattern, an X-linked ataxia gene panel is considered.

General screening tests include brain MRI (to assess the pattern of cerebellar and brainstem atrophy), nerve conduction studies (presence of peripheral neuropathy), electroencephalography (when seizures and myoclonus are present) and blood biochemistry (lactate, pyruvate, vitamin E, lipids, etc.). Gene panel testing or clinical exome sequencing is the standard approach when it is difficult to suspect a single subtype.

9. Diagnosis

Confirmation is by molecular genetic testing according to the suspected subtype. ARSACS is confirmed by full sequencing of the SACS gene (13q11) (SACS is one of the largest human genes, with a coding sequence of about 9.5 kb). DRPLA is diagnosed by analysis of the ATN1 gene CAG repeat number, with an expansion of 49 or more repeats as the diagnostic criterion. CMT-related molecular diagnosis of Roussy-Levy syndrome is made by PMP22 MLPA analysis (duplication/deletion) and sequencing of the MFN2 and MPZ genes.

Subtype-specific findings are identified on brain MRI. In ARSACS, cerebellar atrophy, pontine abnormalities and linear hyperintensity of the Purkinje cell layer on T2-weighted images are characteristic. In DRPLA, atrophy of the brainstem, cerebellum and cerebral white matter is observed, and in the childhood form, cerebellar and basal ganglia atrophy is prominent. Funduscopic examination and optical coherence tomography (OCT) are useful for identifying the retinal abnormalities of ARSACS.

On nerve conduction studies, ARSACS shows a mixed axonal and demyelinating sensorimotor neuropathy, and Roussy-Levy syndrome shows a mainly demyelinating neuropathy pattern. When the cause is unclear, clinical exome or genome sequencing is used as the final diagnostic tool. When pathologic confirmation is needed, skin or nerve biopsy is helpful in some subtypes.

10. Treatment

For most other types of early-onset cerebellar ataxia there is currently no curative treatment, and the goals of treatment are symptom control and maintenance of function. Rehabilitation (physical, occupational and speech therapy) is fundamental in all subtypes. In ARSACS, oral antispasticity agents such as baclofen and tizanidine and botulinum toxin injections are used to treat spasticity. The use of walking aids and ankle-foot orthoses (AFO) helps maintain mobility.

In the childhood form of DRPLA, seizures and myoclonus are controlled with anticonvulsants. Valproic acid, clonazepam and levetiracetam are used. Sodium channel blockers (carbamazepine, phenytoin) can worsen myoclonic seizures and should be avoided. Neuropsychological support and special education for cognitive decline are needed.

Piracetam shows some effect on the myoclonic seizures of myoclonic ataxia (Hunt ataxia). In the form with essential tremor, standard tremor medications such as propranolol and primidone are used. Acetazolamide and 4-aminopyridine may help improve symptoms in some cerebellar ataxia subtypes. Gene therapy research is under way at the preclinical stage for ARSACS and DRPLA.

11. Prognosis

The prognosis of the other types of early-onset cerebellar ataxia varies by subtype. ARSACS tends to progress slowly, but in most cases mobility becomes limited in adulthood; with appropriate treatment and rehabilitation, survival for decades is possible. Roussy-Levy syndrome shows relatively slow progression, and some patients have a stable clinical course.

Childhood-onset DRPLA has a very poor prognosis. Progressive seizures, dementia and functional decline advance rapidly, and age at death varies from the 10s to the 40s but is generally early. The larger the CAG repeat number, the earlier the onset and the faster the progression. The prognosis of myoclonic ataxia varies greatly with the underlying disease, and when based on mitochondrial disease, multisystem involvement may result in a poor prognosis.

Overall, active rehabilitation and prevention of complications are important for maintaining function and quality of life. Psychosocial support and family education contribute to the adaptation of patients and families. Research on disease-modifying treatments such as gene therapy for each subtype is under way, so improved prognosis is expected in the future.

12. Prevention

For the other types of early-onset cerebellar ataxia, blocking genetic transmission is also the key to prevention. The approach differs by the inheritance pattern of each subtype. In autosomal recessive forms (ARSACS, etc.), prenatal diagnosis or PGT-M is possible after carrier testing of both parents and genetic counseling. Siblings of ARSACS patients have a 25% risk of disease, so early genetic testing is recommended.

In autosomal dominant forms (DRPLA, etc.), the patient's children have a 50% risk. Because DRPLA shows strong anticipation, it should be explained during genetic counseling that the age of onset in children may be much earlier. Prenatal diagnosis and PGT-M are means of preventing transmission. In X-linked forms, 50% of the sons of carrier women may be affected, so prenatal sex determination and genetic testing can be used.

After onset, secondary prevention includes fall prevention (orthoses, environmental modification), seizure control and nutritional management. Early detection and multidisciplinary management contribute to prolonging the period of preserved function. Through patient support groups and international networks for each subtype, patients and families can obtain the latest clinical information and support.

13. References

  1. Beaudin M, Depienne C, Manto M, et al. ARSACS: a treatable hereditary ataxia with high prevalence in Quebec. Lancet Neurol. 2022;21(9):788-789. PMID:36117101
  2. Takahashi H, Ikeuchi T, Honma Y, et al. Dentatorubral-pallidoluysian atrophy (DRPLA): clinical features are closely correlated with unstable expansions of the CAG in the DRPLA gene. Ann Neurol. 1998;44(1):78-84. PMID:9667592
  3. Synofzik M, Nemeth AH. Recessive ataxias. Handb Clin Neurol. 2018;155:73-89. PMID:29891062
  4. Giunti P, Mantuano E, Frontali M. Hereditary cerebellar ataxias and related disorders: pathophysiology and therapeutic perspectives. Semin Neurol. 2014;34(3):289-296. PMID:25247594
  5. Harding AE. 'Idiopathic' late onset cerebellar ataxia. A clinical and genetic study of 36 cases. J Neurol Sci. 1981;51(2):259-271. PMID:7276990
  6. Bird TD. Hereditary Ataxia Overview. In: Adam MP, et al., eds. GeneReviews [Internet]. Seattle (WA): University of Washington; 1998. PMID:20301317
  7. Pilch J, Jamroz E, Kozacki J, et al. ARSACS with pontine fibre loss and additional clinical features. Cerebellum. 2012;11(4):1059-1063. PMID:22419088
  8. Obayashi M, Stevanin G, Synofzik M, et al. Progressive Myoclonus Epilepsy. Brain. 2021;144(12):3545-3564. doi:10.1093/brain/awab187
  9. Fogel BL, Perlman S. Clinical features and molecular genetics of autosomal recessive cerebellar ataxias. Lancet Neurol. 2007;6(3):245-257. PMID:17303529
  10. Zeigelboim BS, Klagenberg KF, Stumpf MA, Oliveira CD. ARSACS: a Brazilian case series. Cerebellum Ataxias. 2020;7:10. doi:10.1186/s40673-020-00118-0